A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources

Kamlesh Gidwani, Kaisa Huhtinen, Henna Kekki, Sandra van Vliet, Johanna Hynninen, Niina Koivuviita, Anti Perheentupa, Matti Poutanen, Annika Auranen, Seija Grenman, Urpo Lamminmaki, Olli Carpen, Yvette van Kooyk, Kim Pettersson

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalClinical Chemistry (Washington, DC)
Volume62
Issue number10
Pages (from-to)1390-1400
Number of pages11
ISSN0009-9147
DOIs
Publication statusPublished - Oct 2016
MoE publication typeA1 Journal article-refereed

Fields of Science

  • COLON-CANCER PATIENTS
  • OVARIAN-CANCER
  • GLYCOSYLATION
  • IDENTIFICATION
  • RECOGNITION
  • ANTIGENS
  • RECEPTOR
  • GLYCANS
  • GLYCOME
  • BINDING
  • 217 Medical engineering
  • 3111 Biomedicine

Cite this

Gidwani, K., Huhtinen, K., Kekki, H., van Vliet, S., Hynninen, J., Koivuviita, N., ... Pettersson, K. (2016). A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources. Clinical Chemistry (Washington, DC), 62(10), 1390-1400. https://doi.org/10.1373/clinchem.2016.257691
Gidwani, Kamlesh ; Huhtinen, Kaisa ; Kekki, Henna ; van Vliet, Sandra ; Hynninen, Johanna ; Koivuviita, Niina ; Perheentupa, Anti ; Poutanen, Matti ; Auranen, Annika ; Grenman, Seija ; Lamminmaki, Urpo ; Carpen, Olli ; van Kooyk, Yvette ; Pettersson, Kim. / A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources. In: Clinical Chemistry (Washington, DC). 2016 ; Vol. 62, No. 10. pp. 1390-1400.
@article{f1948a3c38a54b0c921adbf693c3cdd9,
title = "A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources",
keywords = "COLON-CANCER PATIENTS, OVARIAN-CANCER, GLYCOSYLATION, IDENTIFICATION, RECOGNITION, ANTIGENS, RECEPTOR, GLYCANS, GLYCOME, BINDING, 217 Medical engineering, 3111 Biomedicine",
author = "Kamlesh Gidwani and Kaisa Huhtinen and Henna Kekki and {van Vliet}, Sandra and Johanna Hynninen and Niina Koivuviita and Anti Perheentupa and Matti Poutanen and Annika Auranen and Seija Grenman and Urpo Lamminmaki and Olli Carpen and {van Kooyk}, Yvette and Kim Pettersson",
year = "2016",
month = "10",
doi = "10.1373/clinchem.2016.257691",
language = "English",
volume = "62",
pages = "1390--1400",
journal = "Clinical Chemistry (Washington, DC)",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry",
number = "10",

}

Gidwani, K, Huhtinen, K, Kekki, H, van Vliet, S, Hynninen, J, Koivuviita, N, Perheentupa, A, Poutanen, M, Auranen, A, Grenman, S, Lamminmaki, U, Carpen, O, van Kooyk, Y & Pettersson, K 2016, 'A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources', Clinical Chemistry (Washington, DC), vol. 62, no. 10, pp. 1390-1400. https://doi.org/10.1373/clinchem.2016.257691

A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources. / Gidwani, Kamlesh; Huhtinen, Kaisa; Kekki, Henna; van Vliet, Sandra; Hynninen, Johanna; Koivuviita, Niina; Perheentupa, Anti; Poutanen, Matti; Auranen, Annika; Grenman, Seija; Lamminmaki, Urpo; Carpen, Olli; van Kooyk, Yvette; Pettersson, Kim.

In: Clinical Chemistry (Washington, DC), Vol. 62, No. 10, 10.2016, p. 1390-1400.

Research output: Contribution to journalArticleScientificpeer-review

TY - JOUR

T1 - A Nanoparticle-Lectin Immunoassay Improves Discrimination of Serum CA125 from Malignant and Benign Sources

AU - Gidwani, Kamlesh

AU - Huhtinen, Kaisa

AU - Kekki, Henna

AU - van Vliet, Sandra

AU - Hynninen, Johanna

AU - Koivuviita, Niina

AU - Perheentupa, Anti

AU - Poutanen, Matti

AU - Auranen, Annika

AU - Grenman, Seija

AU - Lamminmaki, Urpo

AU - Carpen, Olli

AU - van Kooyk, Yvette

AU - Pettersson, Kim

PY - 2016/10

Y1 - 2016/10

KW - COLON-CANCER PATIENTS

KW - OVARIAN-CANCER

KW - GLYCOSYLATION

KW - IDENTIFICATION

KW - RECOGNITION

KW - ANTIGENS

KW - RECEPTOR

KW - GLYCANS

KW - GLYCOME

KW - BINDING

KW - 217 Medical engineering

KW - 3111 Biomedicine

U2 - 10.1373/clinchem.2016.257691

DO - 10.1373/clinchem.2016.257691

M3 - Article

VL - 62

SP - 1390

EP - 1400

JO - Clinical Chemistry (Washington, DC)

JF - Clinical Chemistry (Washington, DC)

SN - 0009-9147

IS - 10

ER -